1. Home
  2. CUE vs PMVP Comparison

CUE vs PMVP Comparison

Compare CUE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • PMVP
  • Stock Information
  • Founded
  • CUE 2014
  • PMVP 2013
  • Country
  • CUE United States
  • PMVP United States
  • Employees
  • CUE N/A
  • PMVP N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • PMVP Medicinal Chemicals and Botanical Products
  • Sector
  • CUE Health Care
  • PMVP Health Care
  • Exchange
  • CUE Nasdaq
  • PMVP Nasdaq
  • Market Cap
  • CUE 91.9M
  • PMVP 85.5M
  • IPO Year
  • CUE 2018
  • PMVP 2020
  • Fundamental
  • Price
  • CUE $1.44
  • PMVP $1.40
  • Analyst Decision
  • CUE Strong Buy
  • PMVP Strong Buy
  • Analyst Count
  • CUE 5
  • PMVP 3
  • Target Price
  • CUE $5.00
  • PMVP $5.33
  • AVG Volume (30 Days)
  • CUE 270.9K
  • PMVP 161.2K
  • Earning Date
  • CUE 03-10-2025
  • PMVP 02-27-2025
  • Dividend Yield
  • CUE N/A
  • PMVP N/A
  • EPS Growth
  • CUE N/A
  • PMVP N/A
  • EPS
  • CUE N/A
  • PMVP N/A
  • Revenue
  • CUE $9,532,000.00
  • PMVP N/A
  • Revenue This Year
  • CUE $73.11
  • PMVP N/A
  • Revenue Next Year
  • CUE $11.02
  • PMVP N/A
  • P/E Ratio
  • CUE N/A
  • PMVP N/A
  • Revenue Growth
  • CUE 149.53
  • PMVP N/A
  • 52 Week Low
  • CUE $0.45
  • PMVP $1.32
  • 52 Week High
  • CUE $2.58
  • PMVP $2.26
  • Technical
  • Relative Strength Index (RSI)
  • CUE 56.43
  • PMVP 43.76
  • Support Level
  • CUE $1.38
  • PMVP $1.40
  • Resistance Level
  • CUE $1.50
  • PMVP $1.46
  • Average True Range (ATR)
  • CUE 0.12
  • PMVP 0.05
  • MACD
  • CUE 0.00
  • PMVP 0.01
  • Stochastic Oscillator
  • CUE 84.58
  • PMVP 58.29

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

Share on Social Networks: